Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes with Pivotal Phase 2 study // Company appoints physician-scientist Salvatore Alesci as Chief Medical Officer

Contributed by: EQS Newswire

Tags

Dynamics Group AG

More Like This

Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine

Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes

Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout

Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd® in Type 1 Diabetes

Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process

Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026